ReviewNano letters2025
Advancing Lung Cancer Treatment: mRNA Therapeutics and Delivery Strategies.
Review in Nano letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- mRNA-based therapeutics in lung Cancer: Mechanisms, applications, and translational challenges.Journal, genetic engineering & biotechnology · 2026Review
- Endobronchial Intratumoral Immuno- and Gene Therapies in Lung Cancer: Mechanisms of Local Delivery, Systemic Immune Effects, and Global Feasibility.International journal of molecular sciences · 2026Review
- A new era of precision diagnosis and treatment for lung cancer: artificial intelligence-driven multimodal data integration and clinical applications.Cell death & disease · 2026Review
- Steering spherical nucleic acids over metabolic organs for improved targeted drug delivery.Journal of nanobiotechnology · 2026Review
- Personalised neoantigen vaccines for precision oncology in Southeast Asia: clinical opportunities, infrastructure challenges, and policy perspectives.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer tops the list of the deadliest malignancies, consistently resisting conventional therapies and fueling the urgent pursuit of novel treatment strategies. Messenger RNA (mRNA) nanomedicines are rapidly expanding from pandemic vaccinology to oncology, but achieving efficient and targeted delivery to the lung continues to be a significant obstacle. This Mini-Review highlights advances that enable lung-focused mRNA therapeutics. We show extracellular and intracellular barriers, including mucus, surfactant, alveolar macrophages, and endosomal sequestration. We outline how ionizable lipids, polymer-lipid hybrids, extracellular-vesicle mimetics, and selective organ-targeting chemistry overcome these barriers. We overview the therapeutic payload spectrum, from multiepitope vaccines and antibody factories to tumor-suppressor restoration and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.